Answers are grounded in this paper and cite their sources.
Objectives This study aimed to compare the risk of kidney outcomes in patients with gout and type 2 diabetes (T2D) who used sodium-glucose cotransporter-2 inhibitors (SGLT2i) and those who did not. Methods Using the TriNetX US Collaborative Network, we conducted a retrospective cohort study comparing patients with gout and type 2 diabetes who initiated SGLT2i or dipeptidyl peptidase-4 inhibitors (DPP-4i). After 1:1 propensity score matching, 2,676 pairs were included in the primary active-comparator analysis. Kidney outcomes, hospitalization, and all-cause mortality were evaluated using Cox proportional hazards models. A comparison between SGLT2i users and nonusers was retained as a secondary analysis. Results In the primary analysis, SGLT2i initiation was associated with lower risks of composite kidney outcomes (HR, 0.848; 95% CI, 0.775–0.929), incident CKD (HR, 0.851; 95% CI, 0.777–0.932), and all-cause mortality (HR, 0.702; 95% CI, 0.571–0.864) compared with DPP-4i initiation. No statistically significant differences were observed in dialysis or kidney transplantation (HR, 0.685; 95% CI, 0.388–1.210) or all-cause hospitalization (HR, 0.941; 95% CI, 0.857–1.032). Findings from the secondary SGLT2i versus non-SGLT2i analysis were generally consistent. Conclusion Our study found that SGLT2i use in patients with gout and T2D was associated with a lower risk of developing CKD, and all-cause mortality, compared to those not using SGLT2i.
No takes yet. Share an insight, caveat, or question.
Yen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: